They are searching for existing drug repurposing ideas for rare diseases that have yet to receive a full clinical trial. Their primary aim is to demonstrate the huge potential of clinic-led, patient group-led, and researcher-driven innovation in drug repurposing for rare diseases, and the need for new funding streams to help these ideas bridge the translational gap, including Findacure’s Rare Disease Drug Repurposing Social impact Bond (RDDR SIB).
Ideal projects will have some form of collaborator in the UK (note: the PI is not required to be based in the UK), and multinational clinical trials are welcome. For additional eligibility criteria and further information >>>
Deadline for submissions: May, 31 2017
The objective of this call is to support the multinational extension of paediatric studies on medicinal products having already secured funding in the coordinating country.
Hence, if you have a protocol already accepted for funding in Switzerland but you need funding to go abroad, then this call is perfect for you!
All 18 member countries of the PedCRIN consortium are eligible.
Submission deadline: May 2, 2017 | 17.00h CET
The 5th radiz Rare Diseases Summer School will take place in the Tagungszentrum Schloss Au, Wädenswil (on lake Zurich), from June 7th to June 9th 2017.
A wide variety of subjects in the arena of rare diseases will be covered. There will be lectures by national and international rare disease experts, workshops, and poster presentations by participants. Subjects include drug development, model organisms, how to choose clinical endpoints, clinical trials, regulatory aspects, patient registries, patient initiated research, ethical considerations, as well as what rare diseases may tell us about common diseases.
radiz Summer School Flyer >>>
radiz Summer School Program >>>
Please refer to the website for current information.
The application deadline is February 27, 2017.
University Children's Hospital (Universitäts-Kinderspital beider Basel, UKBB), Basel, Switzerland will hold the 3rd annual event for interdisciplinary challenges, preceded by a master class on commercial drug development in the morning of February 1, and a master class on Pediatric Drug development in the afternoon of February 1.
Registration is possible from now on >>>. A first draft agenda and further updates will be sent out in the next weeks and months.
Johannes van den Anker and Klaus Rose, as well as the organizing institutions, are looking forward to welcoming you at DMPRD at the Kinderspital beider Basel.
PELICAN Paediatric End-of-Life Care Needs in Switzerland:
In dieser Tagung werden die Ergebnisse der PELICAN-Studie vorgestellt und Empfehlungen für eine adäquate Gesundheitsversorgung im Bereich der Pädiatrischen Palliative Care diskutiert.
Hier geht es zum Flyer >>>
Nähere Informationen finden Sie hier >>>